title: [Effect of weekly paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide as neoadjuvant treatment for patients with triple-negative and luminal-type breast cancer - a multicenter study].
abstract: This study examined the pathological complete response (pCR )rate and safety of induction chemotherapy with 12 cycles of weekly paclitaxel (80 mg/m²) followed by 4 cycles of 5-fluorouracil (500 mg/m²), epirubicin (100 mg/m²), and cyclo- phosphamide (500 mg/m²). The study medication was administered to female patients (n=31)with a mean age of 51 years, diagnosed with stage II A (n=18), II B (n=11) and III A (n=2) disease and with an estrogen receptor positive rate of 65% (20/31). No patient was HER2-IHC [human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC)](3+) or HER2-FISH (fluorescence in situ hybridization) positive. Twenty-eight patients completed the treatment regimen. Treatment was halted in 2/31 patients due to progression of disease in one patient and a Grade 3 non-hematological adverse effect of skin eruption and itching in the other patient. A third patient died of causes unrelated to the study medication. Central review ascertained a pCR in 6 patients. In patients with triple-negative disease we observed a pCR rate of 67% (6/9). In patients with the Luminal (A+B) subtype, 0% (0/19) had a pCR. Grade 3/4 toxicity included leucopenia (58%), neutropenia (58%), febrile neutropenia (26%), fatigue (10%), and ALT elevation (7%). In terms of pCR, patients presenting with triple-negative disease and manageable safety profiles appear to respond well to this treatment regimen, while only a modest response was observed in patients with Luminal subtype disease.
authors.affiliation: Dept. of Surgery, Kitakyushu Municipal Medical Center.
authors.forename: Keisei
authors.initials: K
authors.lastname: Anan
authors.forename: Maki
authors.initials: M
authors.lastname: Tanaka
authors.forename: Yasuteru
authors.initials: Y
authors.lastname: Yoshinaga
authors.forename: Shigeto
authors.initials: S
authors.lastname: Maeda
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Hayashi
authors.forename: Masaya
authors.initials: M
authors.lastname: Tanaka
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Kamata
authors.forename: Koujirou
authors.initials: K
authors.lastname: Mashino
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Junko
authors.initials: J
authors.lastname: Nishimura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Matsuo
authors.forename: Satoshi
authors.initials: S
authors.lastname: Toyoshima
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tamura
authors.forename: Shoshu
authors.initials: S
authors.lastname: Mitsuyama
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy*
chemical_list: D015251:Epirubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D005472:Fluorouracil